NEW YORK (360Dx) – A team of investigators at the University Hospital of Wales has, in collaboration with PerkinElmer, developed an automated immunoassay that could be used to screen newborns for a biomarker linked to Duchenne muscular dystrophy.

The developers maintain that the new assay would address an unmet market need, and pilot studies are now underway in the US and China, following a successful evaluation of the test in the UK, detailed recently in the journal Clinical Chemistry.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.